Hello everyone, this is my first post here, althou
Post# of 153832
(Total Views: 621)
Posted On: 02/24/2021 8:24:16 AM
Hello everyone, this is my first post here, although I do post elsewhere under the nom de guerre 'Bridge to Sell'. This is a recap of a thought that I recently shared with a friend and fellow CYDY investor. In the interest of full disclosure I have a significant long position in CYDY.
Basically my premise was that in the early days of the CD12 trial we had higher s/c mortality because standard of care had only just begun to be worked out. Naturally that would imply that as time went on mortality in this patient population would start to drop, making it harder to hit statistical relevance. This has been discussed here and elsewhere ad nauseum.
However, because of his success with Leronlimab we had Dr. Nicholas Agresti travelling the country to each of the 18 trial sites in the Fall. Remember, this is the same Dr. Agresti who had a paper accepted in the Journal of Translational Autoimmunity about Leronlimab. Dr. Agresti has been credited with single handedly filling up the second half of the trial and getting us to full enrollment.
So we had a doctor who has successfully used the drug travelling around the country explaining to other doctors how the drug works and on whom they should be targeting it in order to save lives. I believe that it is for that reason alone that we did not see fewer deaths in the second half of the trial because of SOC mitigation. At 195 patient enrollment there were 45 deaths, and at the end of trial there have been 88 deaths for 394 patients.
The ONLY explanation is that Dr. Agresti made sure that the inclusion criteria for the second half of the trial included patients that skewed to more critical than severe. Otherwise standard of care would have dictated that fewer severe patients progressed to critical and deaths as a percentage would have dropped somewhat.
Thanks for reading.
Basically my premise was that in the early days of the CD12 trial we had higher s/c mortality because standard of care had only just begun to be worked out. Naturally that would imply that as time went on mortality in this patient population would start to drop, making it harder to hit statistical relevance. This has been discussed here and elsewhere ad nauseum.
However, because of his success with Leronlimab we had Dr. Nicholas Agresti travelling the country to each of the 18 trial sites in the Fall. Remember, this is the same Dr. Agresti who had a paper accepted in the Journal of Translational Autoimmunity about Leronlimab. Dr. Agresti has been credited with single handedly filling up the second half of the trial and getting us to full enrollment.
So we had a doctor who has successfully used the drug travelling around the country explaining to other doctors how the drug works and on whom they should be targeting it in order to save lives. I believe that it is for that reason alone that we did not see fewer deaths in the second half of the trial because of SOC mitigation. At 195 patient enrollment there were 45 deaths, and at the end of trial there have been 88 deaths for 394 patients.
The ONLY explanation is that Dr. Agresti made sure that the inclusion criteria for the second half of the trial included patients that skewed to more critical than severe. Otherwise standard of care would have dictated that fewer severe patients progressed to critical and deaths as a percentage would have dropped somewhat.
Thanks for reading.
(14)
(0)